Showing results (1-10 of 58) with videos related to
Sort By:
Pageof 6
Clinical Breast Cancer|March 20, 2002
Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccineK L Knutson, M L DisisClinical and Experimental Immunology|January 24, 2004
IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansionK L Knutson, M L DisisCurrent Drug Targets. Immune, Endocrine and Metabolic Disorders|December 27, 2005
Augmenting T helper cell immunity in cancerK L Knutson, M L DisisCancer Immunology, Immunotherapy : CII|July 13, 2005
Tumor antigen-specific T helper cells in cancer immunity and immunotherapyK L Knutson, M L DisisThe Journal of Clinical Investigation|February 22, 2001
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patientsK L Knutson, K Schiffman, M L DisisJournal of Mammary Gland Biology and Neoplasia|March 8, 2000
Immunotherapeutic approaches for the treatment of breast cancerK L Knutson, K Schiffman, K Rinn, et al.Breast Cancer Research and Treatment|November 10, 2000
Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancerM L Disis, K L Knutson, K Schiffman, et al.Critical Reviews in Immunology|October 20, 2001
Clinical translation of peptide-based vaccine trials: the HER-2/neu modelM L Disis, K L Knutson, D G McNeel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2000
Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunizationM L Disis, K Schiffman, T A Gooley, et al.Endocrine-Related Cancer|March 27, 2002
Vaccination against the HER-2/neu oncogenic proteinH Bernhard, L Salazar, K Schiffman, et al.Pageof 6